Clinical Trials

According to clinicaltrials.gov under the U.S. National Institutes of Health, the EU Clinical Trials Register, and the International Clinical Trials Registry Platform under World Health Organization (WHO) the following trials should be recruiting at this moment  (updated December 2021):

A Gene Therapy Study of BMN 331 in Subjects with HAE

– recruiting in the United States


A Study in Teenagers and Adults with HAE Type I or Type II who Use Lanadelumab as Long-Term Prophylaxis

– recruiting in Austria, France, Germany, Greece


A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema with Normal C1-Inhibitor (C1-INH)

– recruiting in Canada, Germany, Hungary, Italy, the Netherlands, Poland, Spain, the United States


A Study of Lanadelumab in Teenagers and Adults with HAE in Argentina

– recruiting in Argentina


A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema with Normal C1- Inhibitor

– recruiting in the United States


A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II

– recruiting in Australia, Canada, Czech Republic, Germany, Hungary, New Zealand, Puerto Rico, the United Kingdom, the United States


Assessment of the State of Health, Quality of Life and Expectations of Patients with HAE

– recruiting in France


Biomarker for HAE Disease

– recruiting in Armenia, Georgia, India, Peru, Poland, Romania, Turkey


C1 Inhibitor Registry in the Treatment of HAE Attacks

– recruiting in Bulgaria, Croatia, Czech Republic, France, Germany, Hungary, Italy, North Macedonia, Norway, Poland, Slovakia, Slovenia, Sweden


Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with HAE

– recruiting in Bulgaria, Canada, Czech Republic, France, Germany, Hungary, Israel, Italy, the Netherlands, Poland, Spain, the United Kingdom, the United States


Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients with HAE Type I or Type II

– recruiting in the United States


Efficacy and Safety of Lanadelumab (SHP643) in Japanese Subjects with HAE

– recruiting in Japan


Epidemiological Analysis for HAE Disease

– recruiting in Germany, Italy, Japan, Poland, Turkey, the United Kingdom


Expanded Access Program with Lanadelumab for Japanese People with HAE

– recruiting in Japan


Firazyr General Drug Use-Results Survey (Japan)

– recruiting in Japan


Firazyr Patient Registry (Icatibant Outcome Survey – IOS)

– recruiting in Australia, Austria, Brazil, Czech Republic, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Spain, Sweden, the United Kingdom


Global Registry to Gather Data on Natural History of Patients with HAE Type I and II

– recruiting in Italy


HAE Kininogen Assay

– recruiting in Germany


Involvement of Monocytic B1 and B2 Receptors in Inflammation and Chronic Vascular Disease in Patients with Hereditary Bradykinetic Angioedema

– recruiting in France


Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of HAE Attacks

– recruiting in Australia, Canada, Czech Republic, Germany, Hong Kong, Hungary, Israel, Japan, the Netherlands, New Zealand, Russia, Spain, the United States


NTLA-2002 in Adults with HAE

– recruiting in New Zealand


Pathophysiological study for autoimmune dysregulation of HAE

– recruiting in Japan


Patient Registry to Evaluate the Real-world Safety of Ruconest

– recruiting in the United States


Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents with HAE

– recruiting in the United States


Study to Evaluate the Real-world Effectiveness of Lanadelumab in Participants with HAE

– recruiting in Canada, Puerto Rico, the United States


Study to Evaluate the Real-World Long-Term Effectiveness of Lanadelumab in Participants with Hereditary Angioedema HAE

– recruiting in Austria, Germany, Israel, Switzerland, the United Kingdom


The influence of stress and lifestyle in HAE

– recruiting in New Zealand


The Role of the Coagulation Pathways in Recurrent Angioedema

– recruiting in France


A Study of the Burden of Illness and Treatment Patterns in Teenagers and Adults with HAE

– will be recruiting


A Study with Lanadelumab in Persons with HAE in Poland

– will be recruiting in Poland


Efficacy and Safety of GNR-038 vs Berinert in Patients with HAE

– will be recruiting in Russia


OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK- LRx) in Participants with HAE

– will be recruiting


Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies

– will be recruiting


Read more about these and other clinical trials at

www.clinicaltrials.gov
www.clinicaltrialsregister.eu
www.apps.who.int/trialsearch

HAE related topics that might interest you

Global Access Program

Helping to change the lives of patients with hereditary angioedema (HAE) with a medication access program

Global Perspectives

Magazine with timely information on the issues, activities, and events that are relevant to the global HAE community

HAEi Connect Member database

Free, secure online membership database and communications platform for HAEi’s member organizations

Regional Patient Advocates

Constantly strive to improve the situation for HAE friends all over the world – no matter how they are organized

Stay tuned – sign up for our newsletter

BE THE FIRST TO KNOW ABOUT HAE NEWS, TREATMENTS, EVENTS AND RELATED TOPICS

Click here to sign up

HAE Global Conference 2018

This 4th HAE conference was record breaking: A total of 736 patients and care givers participated from no less than 57 countries

HAEi hosted websites

Hosting of your national website or help for you to create a new website – naturally all in your native language